Lumbard & Kellner’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-655
Closed -$359K 82
2022
Q1
$359K Sell
655
-126
-16% -$76.1K 0.14% 70
2021
Q4
$516K Buy
781
+6
+0.8% +$4.59K 0.19% 66
2021
Q3
$651K Buy
775
+156
+25% +$158K 0.26% 63
2021
Q2
$786K Sell
619
-61
-9% -$68.8K 0.3% 58
2021
Q1
$746K Sell
680
-177
-21% -$234K 0.26% 60
2020
Q4
$1.22M Buy
+857
New +$914K 0.48% 52

Other funds holding CDLX

Lumbard & Kellner's CDLX Position: Q2 2022 in Review

Lumbard & Kellner sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 655 shares — an estimated $359K sold.

Lumbard & Kellner first reported a position in CDLX in Q4 2020 and held it in 6 quarters. The position peaked at $1.22M in Q4 2020. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.

  • Lumbard & Kellner reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
  • Lumbard & Kellner sold 655 Cardlytics shares in Q2 2022, an estimated $359K.
  • Lumbard & Kellner first reported a position in Cardlytics in Q4 2020 and held it in 6 quarters.
  • Lumbard & Kellner's Cardlytics position peaked at $1.22M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.

Based on Lumbard & Kellner's 13F filing for Q2 2022, filed 15 Aug 2022.